LCM
DSGN icon

Lynx1 Capital Management’s Design Therapeutics DSGN Stock Holding History

Lynx1 Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
119,516
+50,000
+72% +$506K 0.2% 16
2025
Q4 		$652K Buy
69,516
+3,562
+5% +$27.9K 0.13% 16
2025
Q3 		$497K Hold
65,954
– – 0.1% 14
2025
Q2 		$222K Hold
65,954
– – 0.06% 14
2025
Q1 		$255K Buy
+65,954
New +$315K 0.09% 14

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Lynx1 Capital Management's DSGN Position: Q1 2026 in Review

Lynx1 Capital Management increased its Design Therapeutics (DSGN) stake by 72% in Q1 2026, buying an estimated $506K and bringing the position to 119,516 shares worth $1.27M. The position accounts for 0.2% of the portfolio, ranked #16.

Lynx1 Capital Management first reported a position in DSGN in Q1 2025 and has held it in 5 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Lynx1 Capital Management held 119,516 shares of Design Therapeutics worth $1.27M as of Q1 2026.
  • Lynx1 Capital Management bought 50,000 Design Therapeutics shares in Q1 2026, an estimated $506K.
  • Design Therapeutics made up 0.2% of Lynx1 Capital Management's portfolio in Q1 2026, its #16 holding.
  • Lynx1 Capital Management first reported a position in Design Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.